AAVantgarde
AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors.
AAVantgarde's platforms will be clinically validated in two inherited retinal diseases: Usher syndrome type 1B and Stargardt disease. AAVantgarde was co-founded by Professor Alberto Auricchio and originated from the research activities carried out at Tigem (Telethon Institute of Genetics and Medicine) in Naples, Italy, and supported by Sofinnova Partners.
Learn more about AAVantgarde's work towards treatment for USH1B: https://www.aavantgarde.com/en/clinical-trials/usher-1b/
AAVantgarde Related Science News
On September 16, 2024, AAVantgarde announced that the first participant received a dose in the Phase 1/2 LUCE-1 clinical trial for vision loss caused by Usher syndrome type 1B.
MYO7A is a large gene that encodes myosin VIIA, a protein that helps maintain stereocilia in the inner ear and the retinal pigment epithelium in the retina.
